|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shen M and Xu Z, Jiang K, Xu W, Chen Y and
Xu Z: Long noncoding nature brain-derived neurotrophic factor
antisense is associated with poor prognosis and functional
regulation in non-small cell lung caner. Tumor Biol.
39:10104283176959482017. View Article : Google Scholar
|
|
3
|
Hong QY, Wu GM, Qian GS, Hu CP, Zhou JY,
Chen LA, Li WM, Li SY, Wang K, Wang Q, et al: Prevention and
management of lung cancer in China. Cancer. 121 (Suppl
17):S3080–S3088. 2015. View Article : Google Scholar
|
|
4
|
Shu J, Wang L, Han F, Chen Y, Wang S and
Luo F: BTBD7 Downregulates E-cadherin and promotes
epithelial-mesenchymal transition in lung cancer. Biomed Res Int.
2019:59376352019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hoffman RM and Sanchez R: Lung cancer
screening. Med Clin North Am. 101:769–785. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
O'Dowd EL and Baldwin DR: Early diagnosis
pivotal to survival in lung cancer. Practitioner. 258:21–24, 2-3.
2014.
|
|
7
|
Jacobsen MM, Silverstein SC, Quinn M,
Waterston LB, Thomas CA, Benneyan JC and Han PKJ: Timeliness of
access to lung cancer diagnosis and treatment: A scoping literature
review. Lung Cancer. 112:156–164. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guibert N, Tsukada H, Hwang DH, Chambers
E, Cibas ES, Bale T, Supplee J, Ulrich B, Sholl LM, Paweletz CP and
Oxnard GR: Liquid biopsy of fine-needle aspiration supernatant for
lung cancer genotyping. Lung Cancer. 122:72–75. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Heerink WJ, de Bock GH, de Jonge GJ, Groen
HJ, Vliegenthart R and Oudkerk M: Complication rates of CT-guided
transthoracic lung biopsy: Meta-analysis. Eur Radiol. 27:138–148.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Woodard GA, Jones KD and Jablons DM: Lung
cancer staging and prognosis. Cancer Treat Res. 170:47–75. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi YX, Sheng DQ, Cheng L and Song XY:
Current landscape of epigenetics in lung cancer: Focus on the
mechanism and application. J Oncol. 2019:81073182019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jathar S, Kumar V, Srivastava J and
Tripathi V: Technological developments in lncRNA biology. Adv Exp
Med Biol. 1008:283–323. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen R, Li WX, Sun Y, Duan Y, Li Q, Zhang
AX, Hu JL, Wang YM and Gao Y: Comprehensive analysis of lncRNA and
mRNA expression profiles in lung cancer. Clin Lab. 63:313–320.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wei GH and Wang X: lncRNA MEG3 inhibit
proliferation and metastasis of gastric cancer via p53 signaling
pathway. Eur Rev Med Pharmacol Sci. 21:3850–3856. 2017.PubMed/NCBI
|
|
15
|
Zhou Y, Zhang X and Klibanski A: MEG3
noncoding RNA: A tumor suppressor. J Mol Endocrinol. 48:R45–R53.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou Y, Yang H, Xia W, Cui L, Xu R, Lu H,
Xue D, Tian Z, Ding T, Cao Y, et al: LncRNA MEG3 inhibits the
progression of prostate cancer by facilitating H3K27 trimethylation
of EN2 through binding to EZH2. J Biochem. 167:295–301. 2019.
View Article : Google Scholar
|
|
17
|
Zhu X, Zhang HW, Chen HN, Deng XJ, Tu YX,
Jackson AO, Qing JN, Wang AP, Patel V and Yin K: Perivascular
adipose tissue dysfunction aggravates adventitial remodeling in
obese mini pigs via NLRP3 inflammasome/IL-1 signaling pathway. Acta
Pharmacol Sin. 40:46–54. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu JL, Meng FM and Li HJ: High expression
of lncRNA MEG3 participates in non-small cell lung cancer by
regulating microRNA-7-5p. Eur Rev Med Pharmacol Sci. 22:5938–5945.
2018.PubMed/NCBI
|
|
19
|
Zhang Z, Liu T, Wang K, Qu X, Pang Z, Liu
S, Liu Q and Du J: Down-regulation of long non-coding RNA MEG3
indicates an unfavorable prognosis in non-small cell lung cancer:
Evidence from the GEO database. Gene. 630:49–58. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Terashima M, Tange S, Ishimura A and
Suzuki T: MEG3 long noncoding RNA contributes to the epigenetic
regulation of epithelial-mesenchymal transition in lung cancer cell
lines. J Biol Chem. 292:82–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ferrè F, Colantoni A and Helmer-Citterich
M: Revealing protein-lncRNA interaction. Brief Bioinform.
17:106–116. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fernandez-Garcia I, Marcos T,
Muñoz-Barrutia A, Serrano D, Pio R, Montuenga LM and
Ortiz-de-Solorzano C: Multiscale in situ analysis of the role of
dyskerin in lung cancer cells. Integr Biol (Camb). 5:402–413. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Penzo M, Ludovini V, Treré D, Siggillino
A, Vannucci J, Bellezza G, Crinò L and Montanaro L: Dyskerin and
TERC expression may condition survival in lung cancer patients.
Oncotarget. 6:21755–21760. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kulić A, Plavetić ND, Gamulin S,
Jakić-Razumović J, Vrbanec D and Sirotković-Skerlev M: Telomerase
activity in breast cancer patients: Association with poor prognosis
and more aggressive phenotype. Med Oncol. 33:232016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Loewen G, Jayawickramarajah J, Zhuo Y and
Shan B: Functions of lncRNA HOTAIR in lung cancer. J Hematol Oncol.
7:902014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tan BS, Yang MC, Singh S, Chou YC, Chen
HY, Wang MY, Wang YC and Chen RH: LncRNA NORAD is repressed by the
YAP pathway and suppresses lung and breast cancer metastasis by
sequestering S100P. Oncogene. 38:5612–5626. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao Y, Feng C, Li Y, Ma Y and Cai R:
LncRNA H19 promotes lung cancer proliferation and metastasis by
inhibiting miR-200a function. Mol Cell Biochem. 460:1–8. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xia H, Qu XL, Liu LY, Qian DH and Jing HY:
LncRNA MEG3 promotes the sensitivity of vincristine by inhibiting
autophagy in lung cancer chemotherapy. Eur Rev Med Pharmacol Sci.
22:1020–1027. 2018.PubMed/NCBI
|
|
30
|
Zhao Y, Zhu Z, Shi S, Wang J and Li N:
Long non-coding RNA MEG3 regulates migration and invasion of lung
cancer stem cells via miR-650/SLC34A2 axis. Biomed Pharmacother.
120:1094572019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang M, Pan Y, Jiang R, Hou P, Shan H,
Chen F, Jiang T, Bai J and Zheng J: DKC1 serves as a potential
prognostic biomarker for human clear cell renal cell carcinoma and
promotes its proliferation, migration and invasion via the NF-κB
pathway. Oncol Rep. 40:968–978. 2018.PubMed/NCBI
|
|
32
|
Liu B, Zhang J, Huang C and Liu H:
Dyskerin overexpression in human hepatocellular carcinoma is
associated with advanced clinical stage and poor patient prognosis.
PLoS One. 7:e431472012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nersisyan L, Hopp L, Loeffler-Wirth H,
Galle J, Loeffler M, Arakelyan A and Binder H: Telomere length
maintenance and its transcriptional regulation in lynch syndrome
and sporadic colorectal carcinoma. Front Oncol. 9:11722019.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Richards LA, Kumari A, Knezevic K, Thoms
JA, von Jonquieres G, Napier CE, Ali Z, O'Brien R, Marks-Bluth J,
Maritz MF, et al: DKC1 is a transcriptional target of GATA1 and
drives upregulation of telomerase activity in normal human
erythroblasts. Haematologica. 105:1517–1526. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bernardes de Jesus B and Blasco MA:
Telomerase at the intersection of cancer and aging. Trends Gene.
29:513–520. 2013. View Article : Google Scholar
|
|
36
|
Mizukoshi E and Kaneko S:
Telomerase-targeted cancer immunotherapy. Int J Mol Sci.
20:18232019. View Article : Google Scholar
|
|
37
|
Yuan X, Larsson C and Xu D: Mechanisms
underlying the activation of TERT transcription and telomerase
activity in human cancer: Old actors and new players. Oncogene.
38:6172–6183. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Miao FA, Chu K, Chen HR, Zhang M, Shi PC,
Bai J and You YP: Increased DKC1 expression in glioma and its
significance in tumor cell proliferation, migration and invasion.
Invest New Drugs. 37:1177–1186. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Penzo M, Casoli L, Ceccarelli C, Treré D,
Ludovini V, Crinò L and Montanaro L: DKC1 gene mutations in human
sporadic cancer. Histol Histopathol. 28:365–372. 2013.PubMed/NCBI
|
